SU5214 is primarily utilized in research settings as a potent inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2). It plays a crucial role in studying angiogenesis, the process by which new blood vessels form from pre-existing vessels. By inhibiting VEGFR-2, SU5214 helps researchers understand the mechanisms of tumor growth and metastasis, as angiogenesis is a critical factor in cancer progression. Additionally, it is used in preclinical studies to evaluate the efficacy of anti-angiogenic therapies, providing insights into potential treatments for various cancers and other diseases characterized by abnormal blood vessel formation. Its application extends to exploring the role of VEGFR-2 in other pathological conditions, such as rheumatoid arthritis and diabetic retinopathy, where angiogenesis is also a contributing factor.